NewAmsterdam Pharma (NASDAQ:NAMS) Shares Bought by M&T Bank Corp

M&T Bank Corp lifted its holdings in shares of NewAmsterdam Pharma (NASDAQ:NAMS) by 54.1% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 27,328 shares of the company’s stock after acquiring an additional 9,593 shares during the quarter. M&T Bank Corp’s holdings in NewAmsterdam Pharma were worth $454,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also recently added to or reduced their stakes in NAMS. Banque Cantonale Vaudoise purchased a new position in NewAmsterdam Pharma in the second quarter valued at about $38,000. Quarry LP raised its holdings in shares of NewAmsterdam Pharma by 2,469.2% during the 3rd quarter. Quarry LP now owns 6,500 shares of the company’s stock valued at $108,000 after buying an additional 6,247 shares during the period. Barclays PLC lifted its position in NewAmsterdam Pharma by 1,813.4% during the 3rd quarter. Barclays PLC now owns 7,596 shares of the company’s stock worth $126,000 after acquiring an additional 7,199 shares in the last quarter. Bellevue Group AG purchased a new position in NewAmsterdam Pharma in the 3rd quarter worth approximately $128,000. Finally, XTX Topco Ltd acquired a new stake in NewAmsterdam Pharma in the third quarter valued at approximately $187,000. 89.89% of the stock is owned by hedge funds and other institutional investors.

NewAmsterdam Pharma Trading Up 7.7 %

NASDAQ NAMS opened at $26.61 on Wednesday. NewAmsterdam Pharma has a 12 month low of $10.12 and a 12 month high of $27.29. The company’s fifty day moving average price is $20.84 and its two-hundred day moving average price is $18.81.

Insider Transactions at NewAmsterdam Pharma

In other NewAmsterdam Pharma news, major shareholder Nap B.V. Forgrowth sold 8,530 shares of the business’s stock in a transaction on Friday, November 15th. The shares were sold at an average price of $25.02, for a total transaction of $213,420.60. Following the completion of the sale, the insider now owns 11,812,033 shares in the company, valued at $295,537,065.66. The trade was a 0.07 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CAO Louise Frederika Kooij sold 45,000 shares of the firm’s stock in a transaction dated Tuesday, October 1st. The stock was sold at an average price of $15.72, for a total transaction of $707,400.00. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 252,814 shares of company stock valued at $5,970,327. Insiders own 19.50% of the company’s stock.

Analyst Ratings Changes

Several brokerages have recently weighed in on NAMS. Piper Sandler restated an “overweight” rating and issued a $37.00 target price on shares of NewAmsterdam Pharma in a research note on Monday, September 23rd. Scotiabank upped their price objective on shares of NewAmsterdam Pharma from $35.00 to $47.00 and gave the company a “sector outperform” rating in a research report on Wednesday, December 11th. Royal Bank of Canada reaffirmed an “outperform” rating and set a $31.00 target price on shares of NewAmsterdam Pharma in a research report on Thursday, September 5th. Finally, Needham & Company LLC reissued a “buy” rating and issued a $36.00 price target on shares of NewAmsterdam Pharma in a report on Thursday, December 5th. Six research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock currently has a consensus rating of “Buy” and an average price target of $36.20.

NewAmsterdam Pharma Profile

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases.